List view / Grid view
29 June 2015 | By Victoria White
The CHMP has recommended that the EC approves the use of Perjeta for the neoadjuvant treatment of adult patients with HER2-positive early breast cancer...
23 June 2015 | By Victoria White
Roche has announced new data from the first study of the novel humanised bispecific antibody ACE910 (RG6013) in people with severe haemophilia A...
18 June 2015 | By Victoria White
Roche has been selected to provide HIV-1 viral load and early infant diagnostic technologies for the Global Fund...
10 June 2015 | By Victoria White
The FDA has granted Breakthrough Therapy designation status to Roche’s ACTEMRA/RoACTEMRA (tocilizumab) for systemic sclerosis (SSc)...
2 June 2015 | By Victoria White
Amgen and Roche are to collaborate on a study to evaluate talimogene laherparepvec in combination with atezolizumab in patients with cancer...
From today, clinicians in England and Wales will be able to prescribe Roche's Gazyvaro for eligible patients with chronic lymphocytic leukaemia (CLL) on the NHS.
1 June 2015 | By Victoria White
Results from a Phase III study show that Gazyvaro provided significant benefit for people with indolent non-Hodgkin’s lymphoma (NHL)...
1 June 2015 | By Victoria White
Roche has announced new results from the Phase II NeoSphere study that assessed a Perjeta regimen in people with HER2-positive early breast cancer...
14 May 2015 | By Victoria White
Roche has announced interim results from a global, randomised Phase II study (POPLAR) of MPDL3280A in people with previously treated NSCLC...
14 May 2015 | By Victoria White
Results from two pivotal studies have shown that alectinib shrank tumours in people with advanced ALK-positive (ALK+) non-small cell lung cancer (NSCLC)...
11 May 2015 | By Victoria White
Roche has announced that data from 10 of its approved cancer medicines and 10 of its investigational medicines will be presented at this year’s American Society of Clinical Oncology Annual Meeting (ASCO 2015).
7 May 2015 | By Victoria White
The FDA has granted Breakthrough Therapy Designation for venetoclax for the treatment of people who have relapsed or refractory CLL with 17p deletion...
8 April 2015 | By Victoria White
The EU has approved Avastin in combination with chemotherapy for the treatment of persistent, recurrent or metastatic carcinoma of the cervix...
11 March 2015 | By Roche
New option for patients as NICE accepts Gazyvaro® (obinutuzumab) for treatment of most common adult leukaemia...
4 March 2015 | By Roche
Roche announced that its Ordinary Annual General Meeting has voted in favour of all of the Board of Directors’ proposals...
